Asia-Pacific Molecular Diagnostics Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Asia-Pacific Molecular Diagnostics Market Size

• The Asia-Pacific molecular diagnostics market size was valued at USD 9.47 billion in 2025 and is expected to reach USD 16.02 billion by 2033, at a CAGR of 6.8% during the forecast period
• The market growth is primarily driven by increasing prevalence of infectious diseases and genetic disorders, coupled with rising healthcare expenditure and adoption of advanced diagnostic technologies across countries such as China, India, Japan, and Australia
• Moreover, growing government initiatives to enhance early disease detection, rising awareness about personalized medicine, and the expanding network of diagnostic laboratories are positioning molecular diagnostics as a critical component of modern healthcare. These factors are collectively propelling market expansion throughout the Asia-Pacific region

Asia-Pacific Molecular Diagnostics Market Analysis

• Molecular diagnostics, encompassing techniques such as PCR, next-generation sequencing, and immunoassays, are becoming increasingly vital in early disease detection, personalized medicine, and infectious disease management across both clinical and research settings due to their high sensitivity, specificity, and rapid turnaround times
• The rising demand for molecular diagnostics in the region is primarily fueled by increasing prevalence of infectious and chronic diseases, growing awareness about early diagnosis, government initiatives supporting healthcare infrastructure, and expanding adoption of advanced diagnostic technologies
• China dominated the Asia-Pacific molecular diagnostics market with the largest revenue share of 42.5% in 2025, characterized by large patient populations, rising healthcare expenditure, and a robust network of diagnostic laboratories
• India is expected to be the fastest growing country in the molecular diagnostics market during the forecast period driven by increasing investments in healthcare infrastructure, rising disposable incomes, and expanding access to advanced diagnostic technologies
• Polymerase Chain Reaction (PCR)-based methods segment dominated the molecular diagnostics market in Asia-Pacific with a market share of 40.9% in 2025, driven by their widespread use in infectious disease detection, cancer diagnostics, and genetic testing, as well as their adaptability to point-of-care and high-throughput laboratory settings

Report Scope and Asia-Pacific Molecular Diagnostics Market Segmentation 

Asia-Pacific Molecular Diagnostics Market Trends

Advancements in AI-Driven and Point-of-Care Testing

• A significant and accelerating trend in the Asia-Pacific molecular diagnostics market is the integration of artificial intelligence (AI) and automation into diagnostic platforms, enabling faster, more accurate, and high-throughput testing for infectious diseases, cancer, and genetic disorders
  • For instance, Thermo Fisher Scientific’s AI-enabled PCR platforms in India and China optimize assay workflows, reducing turnaround time while improving result accuracy for laboratories and hospitals
• AI-driven diagnostics also allow predictive analytics, helping laboratories anticipate disease outbreaks or identify high-risk patients for personalized treatment. For instance, QIAGEN’s AI-assisted sequencing platforms in China leverage pattern recognition to support oncology and infectious disease testing
• The growing adoption of portable and point-of-care (POC) molecular diagnostic devices is facilitating decentralized testing, particularly in remote or underserved regions. Through handheld or benchtop systems, healthcare providers can perform rapid diagnostics outside traditional labs
• This trend towards smarter, faster, and decentralized molecular testing is transforming clinical practices and laboratory workflows, leading companies such as Cepheid to develop AI-assisted POC PCR systems with rapid pathogen detection and automated reporting capabilities
• The demand for AI-integrated and POC molecular diagnostic tools is rising rapidly across hospitals, diagnostic centers, and research institutes in Asia-Pacific as accuracy, speed, and accessibility become critical priorities
• In addition, cloud-based data integration is emerging as a trend, allowing molecular diagnostic results to be automatically uploaded, shared, and analyzed for epidemiological tracking and real-time clinical decision-making

Asia-Pacific Molecular Diagnostics Market Dynamics

Driver

Increasing Demand Due to Rising Disease Burden and Healthcare Investments

• The growing prevalence of infectious diseases, genetic disorders, and cancer in Asia-Pacific, combined with rising healthcare spending, is a key driver for the increased adoption of molecular diagnostic solutions
  • For instance, in March 2025, QIAGEN expanded its presence in India with new laboratory automation systems, aiming to support high-throughput COVID-19 and oncology testing
• As healthcare providers prioritize early diagnosis and personalized treatment, molecular diagnostics offer high sensitivity, specificity, and rapid results, outperforming conventional testing methods
• Furthermore, government initiatives supporting disease screening programs and infrastructure development are enabling wider adoption of molecular testing platforms across public and private hospitals
• The ease of integration with laboratory information systems, automation for sample processing, and the availability of user-friendly molecular diagnostic kits are key factors accelerating adoption in both urban and rural healthcare facilities
  • For instance, Roche Diagnostics’ expansion of Cobas systems in Southeast Asia is increasing access to automated molecular testing for infectious diseases and oncology
• In addition, growing partnerships between diagnostic companies and healthcare providers for training programs and technical support are enhancing adoption and operational efficiency across Asia-Pacific laboratories
• Increasing awareness campaigns for early disease detection and personalized medicine in countries such as India and China are driving patient demand for molecular diagnostic testing

Restraint/Challenge

High Cost, Infrastructure Limitations, and Regulatory Hurdles

• The relatively high cost of advanced molecular diagnostic instruments and reagents poses a significant challenge to wider adoption, especially in developing countries within Asia-Pacific
  • For instance, high-end next-generation sequencing platforms may be unaffordable for smaller diagnostic labs in India or Southeast Asia, limiting their deployment
• Inadequate laboratory infrastructure and shortage of skilled personnel further constrain market growth, particularly in rural or semi-urban regions. For instance, training requirements for AI-assisted diagnostic platforms can delay implementation in regional hospitals
• Regulatory compliance and approvals for new molecular diagnostic assays can be time-consuming, creating entry barriers for smaller companies or innovative technologies
• While costs are gradually declining and governments are investing in healthcare modernization, addressing infrastructure gaps, workforce training, and streamlined regulatory processes will be essential for sustained growth in the Asia-Pacific molecular diagnostics market
• For instance, lengthy approval processes for COVID-19 rapid molecular tests in India delayed market introduction, highlighting regulatory bottlenecks
• Limited awareness among healthcare providers and patients about advanced molecular diagnostic options in emerging economies further slows adoption despite availability of modern technologies

Asia-Pacific Molecular Diagnostics Market Scope

The market is segmented on the basis of products, technology, application, and end user.

• By Products

On the basis of products, the market is segmented into reagents & kits, instruments, and services & software. The reagents & kits segment dominated the market with the largest market revenue share of 45% in 2025, driven by the recurring need for consumables in molecular testing and their critical role in PCR, NGS, and other diagnostic workflows. Reagents and kits are widely adopted across hospitals, clinical labs, and research centers for disease detection and screening. The segment benefits from frequent updates and innovations in assay design, high specificity, and compatibility with automated diagnostic instruments. Strong demand for multiplex assays and COVID-19-related testing further propelled revenue. In addition, easy availability of ready-to-use kits reduces operational complexity for laboratories. The segment’s dominance is reinforced by established manufacturers such as Thermo Fisher, QIAGEN, and Roche, supplying a broad range of kits to the region.

The instruments segment is anticipated to witness the fastest growth at a CAGR of 13.2% from 2026 to 2033, fueled by increasing automation in laboratories and the growing adoption of high-throughput testing platforms. Instruments such as PCR thermocyclers, sequencers, and point-of-care devices are increasingly being deployed in hospitals and academic centers. Rising investments in laboratory modernization, particularly in India and China, are driving instrument sales. Integration with AI and cloud-based platforms for real-time data management is boosting adoption. Instruments enable faster testing, scalability, and precision, making them attractive for both clinical diagnostics and research applications. New product launches and localized manufacturing further support growth in this segment.

• By Technology

On the basis of technology, the market is segmented into PCR-based methods, next-generation sequencing (NGS), chips and microarray, mass spectrometry (MS), capillary electrophoresis, cytogenetics, in situ hybridization (ISH/FISH), molecular imaging, and others. The PCR-based methods segment dominated the market with the largest revenue share of 40.9% in 2025, driven by their widespread application in infectious disease testing, oncology, and genetic disorder detection. PCR is preferred for its high sensitivity, specificity, and rapid turnaround, making it a standard in clinical and research laboratories. It is easily scalable for high-throughput testing and compatible with automated platforms. The prevalence of COVID-19 and other infectious diseases has further solidified PCR’s dominance. Reagent kits, instruments, and consumables linked to PCR workflows continue to generate steady revenue. PCR’s adaptability for both point-of-care and centralized lab testing contributes to its sustained leadership.

The next-generation sequencing (NGS) segment is expected to witness the fastest growth at a CAGR of 14.5% from 2026 to 2033, fueled by rising demand for precision medicine and oncology applications. NGS enables comprehensive genomic profiling, early detection of genetic disorders, and targeted therapy selection. Decreasing sequencing costs and improved bioinformatics pipelines are accelerating adoption across hospitals and academic centers. Collaborations between NGS companies and healthcare providers are expanding market reach in China, India, and Japan. NGS’s application in prenatal testing, rare disease diagnosis, and infectious disease surveillance is increasing. Continuous innovation in high-throughput sequencers and AI-driven data analysis platforms supports rapid growth.

• By Application

On the basis of application, the market is segmented into oncology, pharmacogenomics, microbiology, prenatal tests, tissue typing, blood screening, cardiovascular diseases, neurological diseases, infectious diseases, and others. The oncology segment dominated the market with the largest revenue share of 35% in 2025, driven by the increasing prevalence of cancer and rising adoption of molecular diagnostics for early detection, therapy selection, and monitoring. Oncology testing requires advanced molecular assays such as PCR, NGS, and FISH, which are widely used in hospitals and clinical labs. Growing awareness of personalized medicine and targeted therapies supports high market demand. Government initiatives and reimbursement policies in China, India, and Japan further facilitate adoption. The availability of high-quality reagents and instruments ensures reliable and scalable testing. Strong partnerships between diagnostic companies and oncology hospitals strengthen market leadership.

The infectious diseases segment is expected to witness the fastest growth at a CAGR of 13.8% from 2026 to 2033, driven by increasing prevalence of viral and bacterial infections and rising demand for rapid, accurate diagnostics. Point-of-care molecular tests for diseases such as COVID-19, hepatitis, and influenza are expanding market penetration. Government screening programs and hospital preparedness initiatives support growth in India, China, and Southeast Asia. Portable PCR and POC devices enable decentralized testing, especially in rural and semi-urban areas. Integration with AI for predictive outbreak monitoring further accelerates adoption. Increasing awareness about early detection and treatment of infectious diseases contributes to rapid expansion.

• By End User

On the basis of end user, the market is segmented into hospitals, clinical laboratories, and academic & research institutes. The hospitals segment dominated the market with the largest revenue share of 46% in 2025, driven by the high demand for molecular diagnostics in routine testing, disease management, and personalized therapy. Hospitals require rapid, accurate testing for patient care, including oncology, infectious disease, and genetic disorder diagnostics. Adoption of automated platforms, point-of-care testing, and AI-enabled molecular instruments enhances hospital efficiency. Rising investments in hospital infrastructure in China, India, and Japan support growth. Partnerships with diagnostic companies for training and technical support increase utilization. Hospitals’ focus on patient-centered care and early diagnosis ensures consistent demand.

The clinical laboratories segment is expected to witness the fastest growth at a CAGR of 12.9% from 2026 to 2033, fueled by outsourcing trends, high testing volumes, and specialized molecular diagnostic services. Clinical labs benefit from automation, high-throughput platforms, and connectivity with hospital information systems. Expansion of private diagnostic chains in India, China, and Southeast Asia is driving adoption. Laboratories increasingly utilize NGS and AI-assisted PCR platforms for oncology, infectious diseases, and prenatal testing. Growing awareness among clinicians and patients about early detection supports rapid growth. Collaboration with molecular diagnostics vendors for reagent and instrument supply further boosts adoption.

Asia-Pacific Molecular Diagnostics Market Regional Analysis

• China dominated the Asia-Pacific molecular diagnostics market with the largest revenue share of 42.5% in 2025, characterized by large patient populations, rising healthcare expenditure, and a robust network of diagnostic laboratories
• Hospitals, clinical laboratories, and research institutes in China are increasingly adopting advanced molecular diagnostic technologies such as PCR, NGS, and AI-enabled platforms for early disease detection, personalized medicine, and oncology testing
• This widespread adoption is further supported by strong government initiatives promoting disease screening programs, investments in healthcare infrastructure, and growing public awareness about the benefits of molecular diagnostics, establishing China as a key hub for molecular testing in the region

The China Molecular Diagnostics Market Insight

The China molecular diagnostics market captured the largest revenue share of 42.5% in 2025 within Asia-Pacific, fueled by a growing prevalence of infectious and chronic diseases, rising healthcare expenditure, and a robust network of diagnostic laboratories. Healthcare providers and research institutes are increasingly adopting advanced molecular diagnostic technologies such as PCR, NGS, and AI-assisted platforms for early disease detection, oncology testing, and genetic disorder screening. The country’s government initiatives supporting disease surveillance, personalized medicine, and laboratory modernization are further accelerating market adoption. In addition, increasing awareness among clinicians and patients about rapid and accurate testing is strengthening demand. China’s established domestic and international diagnostic companies are expanding their footprint through collaborations, driving innovation and accessibility. The availability of automated platforms and high-throughput instruments is enhancing efficiency and scalability in molecular testing workflows.

Japan Molecular Diagnostics Market Insight

The Japan molecular diagnostics market is gaining momentum due to the country’s advanced healthcare infrastructure, high technological adoption, and aging population driving demand for early detection and precision medicine. Hospitals, clinical laboratories, and academic centers are increasingly deploying NGS, PCR-based assays, and point-of-care molecular diagnostic systems. Integration with AI and data analytics platforms allows faster and more accurate results, supporting oncology, infectious disease, and prenatal testing. Government initiatives promoting health monitoring and preventive diagnostics further propel growth. Japan’s focus on innovation and quality encourages adoption of high-end instruments and reagents. The increasing prevalence of chronic diseases, coupled with rising awareness of personalized healthcare, is expanding the use of molecular diagnostics across clinical and research settings.

India Molecular Diagnostics Market Insight

The India molecular diagnostics market accounted for the largest revenue share in Asia-Pacific in 2025 after China, attributed to rapid urbanization, a growing middle-class population, and increasing healthcare spending. Hospitals, diagnostic laboratories, and research institutes are adopting PCR, NGS, and AI-assisted molecular diagnostic platforms for infectious disease detection, oncology, and genetic testing. The country’s government initiatives promoting smart healthcare infrastructure and disease screening programs are boosting market penetration. India is emerging as a key hub for affordable point-of-care molecular diagnostic solutions, making testing accessible to urban and semi-urban populations. Strong domestic manufacturers and partnerships with global diagnostic companies are further driving growth. Increasing awareness among clinicians and patients about early detection and personalized medicine is encouraging adoption across the healthcare ecosystem.

Australia Molecular Diagnostics Market Insight

The Australia molecular diagnostics market is witnessing steady growth driven by high healthcare standards, advanced laboratory infrastructure, and rising adoption of next-generation molecular diagnostic technologies. Hospitals and research institutions are increasingly using PCR, NGS, and AI-enabled platforms for oncology, infectious diseases, and genetic testing. Government initiatives promoting preventive healthcare, personalized medicine, and early disease detection are fueling market demand. Integration of molecular diagnostics with digital health platforms and hospital information systems is enhancing efficiency and data management. The country’s strong focus on innovation and research supports the introduction of new diagnostic assays and instruments. Rising patient awareness about rapid and accurate diagnostics is further contributing to market expansion.

Asia-Pacific Molecular Diagnostics Market Share

The Asia-Pacific Molecular Diagnostics industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• BIOMÉRIEUX (France)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Meridian Bioscience, Inc. (U.S.)
• Illumina, Inc. (U.S.)
• Siemens Healthineers AG (Germany)
• Hologic, Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• BD (U.S.)
• DiaSorin S.p.A. (Italy)
• Quidel Corporation (U.S.)
• SD Biosensor, Inc. (South Korea)
• Mindray Medical International (China)
• Astragene (U.A.E.)
• Euroimmun Medizinische Labordiagnostika AG (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• QIAGEN (Netherlands)
• Danaher (U.S.)

What are the Recent Developments in Asia-Pacific Molecular Diagnostics Market?

• In May 2025, Gene Solutions and NEWCL Biomedical Laboratory forged a strategic partnership to establish an advanced next‑generation sequencing (NGS) laboratory in Taiwan, expanding access to sophisticated genetic testing for prenatal care and precision oncology
• In February 2023, Thermo Fisher Scientific announced the launch of Applied Biosystems™ TaqPath real‑time PCR kits for the detection of multiple infectious diseases in India, including multi‑drug‑resistant tuberculosis (MTB MDR), hepatitis B and C, HIV, and genetic analysis (HLA B27). The kits are manufactured locally in partnership with Mylab Discovery Solutions, strengthening molecular testing capacity in the region and supporting clinical diagnostics labs with a comprehensive qPCR workflow solution
• In February 2023, Thermo Fisher Scientific’s Applied Biosystems TaqPath PCR kits for infectious disease detection received licensing and clinical validation in India for use in patient care, including disease screening, therapeutic monitoring, and genetic risk identification boosting local diagnostic capabilities across major disease areas
• In December 2021, Roche launched new infectious disease molecular tests and the cobas omni Utility Channel on the cobas 5800 system in countries with CE Mark acceptance, enabling laboratories in Asia‑Pacific to run CE‑IVD assays or design customized laboratory developed tests (LDTs) and expanding access to robust diagnostics tools in high burden regions
• In May 2021, Cipla Inc. (India) introduced ViraGen, an RT‑PCR test kit for the detection of the coronavirus, aimed at enhancing molecular diagnostic testing capacity during the COVID‑19 pandemic by providing rapid and accurate virus detection to support public health screening and clinical management

SKU-64284